Livforsakringsbolaget Skandia Omsesidigt Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY

Livforsakringsbolaget Skandia Omsesidigt lessened its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 79.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,600 shares of the company’s stock after selling 40,800 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Harmony Biosciences were worth $396,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in Harmony Biosciences by 6.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,691,581 shares of the company’s stock valued at $46,620,000 after buying an additional 109,405 shares during the last quarter. American Century Companies Inc. increased its holdings in Harmony Biosciences by 11.2% in the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock valued at $46,013,000 after buying an additional 168,145 shares during the last quarter. LSV Asset Management increased its holdings in Harmony Biosciences by 3.9% in the fourth quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after buying an additional 62,200 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Harmony Biosciences by 42.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock valued at $35,701,000 after buying an additional 388,472 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Harmony Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 1,270,586 shares of the company’s stock valued at $47,551,000 after buying an additional 12,323 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HRMY shares. HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a report on Friday, May 22nd. Truist Financial raised their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. UBS Group dropped their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft lowered Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Monday, February 23rd. Finally, Weiss Ratings lowered Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Harmony Biosciences currently has a consensus rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $32.20 on Friday. The stock’s 50-day moving average is $30.16 and its two-hundred day moving average is $33.12. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.23 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21). The firm had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.